(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2013 (26.09.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/138850 A1

(51) International Patent Classification:
C12N 15/63 (2006.01) *C12N 15/70* (2006.01)
C12N 15/62 (2006.01) *C07K 19/00* (2006.01)

(21) International Application Number:
PCT/AU2013/000273

(22) International Filing Date:
19 March 2013 (19.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/612,817 19 March 2012 (19.03.2012) US

(71) Applicant: **MADELEINE PHARMACEUTICALS PTY LTD** [AU/AU]; Lot 24, Williams Road, Summit Fire Track, Mount Barker, South Australia 5251 (AU).

(72) Inventors: **BASTIRAS, Stan**; 21 Bonython Close, Adelaide, South Australia 5000 (AU). **GUIDOLIN, Angelo**; 31 Oxenbould Street, Parkside, South Australia 5063 (AU). **HUNT, Ben**; 43 Currawong Crescent, Modbury North, South Australia 5092 (AU). **RAISHEED, Saif**; 9/465 Portrush Road, Glenside, South Australia 5065 (AU). **ZAREIE, Reza**; 30 Otram Way, Churchlands, Western Australia 6018 (AU).

(74) Agent: **MADDERNS PATENT AND TRADE MARK ATTORNEYS**; GPO Box 2752, Adelaide, South Australia 5001 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: METHOD OF PRODUCING A RECOMBINANT PEPTIDE

Figure 3b



(57) **Abstract**: Methods of producing a recombinant peptide, such as vessel dilator peptide (VSDL), are disclosed, including a particular method involving expressing a fusion polypeptide comprising concatemeric repeats of the peptide wherein the peptide is flanked by peptide cleavage sites, and cleaving the fusion polypeptide at the peptide cleavage sites with a cleaving agent(s) so as to release the peptide from the fusion polypeptide. Expression constructs and host cells for producing the fusion polypeptide and purification methods for the recombinant peptide are also disclosed.

WO 2013/138850 A1